Skip to content
Screener

Total Revenue at other companies

Eli Lilly logo
Eli LillyLLY
$22.97B+47.7%
Pfizer logo
PfizerPFE
$15.03B+2.6%
Amgen logo
AmgenAMGN
$10.05B+9.5%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$29.11M-2.1%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$364.25M+71.2%
Altimmune logo
AltimmuneALT
$26K+420%

Other financials

Income statement

See full
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$3.88B+8.4%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026. Open the filing →

Filed
Apr 29, 2026, 9:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-193315

FAQ

What is Viking Therapeutics's total revenue?
Viking Therapeutics (VKTX) reported total revenue of $0 in Q1 2026.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Viking Therapeutics's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude